EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.
about
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
P2860
EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
EGFR targeting monoclonal anti ...... complementary signaling hubs.
@en
type
label
EGFR targeting monoclonal anti ...... complementary signaling hubs.
@en
prefLabel
EGFR targeting monoclonal anti ...... complementary signaling hubs.
@en
P2093
P2860
P356
P1433
P1476
EGFR targeting monoclonal anti ...... complementary signaling hubs.
@en
P2093
Chetana Basavaraj
Enrique Montero
Indira V Chivukula
Pradip Nair
Ramakrishnan Melarkode
Roshan James
Siddharth Vishwakarma
P2860
P304
P356
10.1002/CAM4.21
P407
P577
2012-08-01T00:00:00Z